Generics firm Alvogen is putting its Central and Eastern European (CEE) operations up for sale as its private equity owners seek a step-by-step exit from the maker of drugs against cancer, heart and lung diseases, people close to the matter said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
